Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is a phase IIa dose-ranging, randomized, double-blind, chronic-dosing (14 Days),
three-period, placebo-controlled, multi-center, cross-over study to assess the efficacy and
safety of two dose levels of a dual pharmacology molecule with the combined properties of a
long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA); (AZD2115)
delivered by a metered-dose inhaler (MDI) in subjects with moderate to severe chronic
obstructive pulmonary disease (COPD).